Imprivata Inc (NYSE:IMPR)’s average revenue estimates for the current quarter are 33.37M according to 8 number of analysts. During the same quarter in the previous year, the company posted $-0.24 EPS. Moreover, Paradigm Capital Management Inc Ny has 1.18% invested in the company for 803,300 shares. NY increased its stake in Imprivata by 1,270.4% in the fourth quarter. Company has a market cap of $481 M.
Advertisement
According to Robbins Arroyo, the merger consideration of $19.25 is below the target price of $20 that an analyst at Stifel has on the shares of Imprivata. The deal is valued at approximately $544 million.
Shares of Archer Daniels Midland Company (NYSE:ADM) declined -0.44% to $43.10.
If you own shares of Imprivata stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. Also, SVP Thomas W. Brigiotta sold 10,000 shares of the company’s stock in a transaction dated Monday, April 18th. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move.
02/17/2016 – Imprivata, Inc. had its “overweight” rating reiterated by analysts at Barclays. Imprivata Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 13, 2016. The stock has received “Buy” rating after consensus analysis from analysts.
Imprivata now sits at a Zacks Rank #1 (Strong Buy).
The share price of Imprivata, Inc. On a one to five ratings scale where 1.0 indicates a Strong Buy, 2.0 indicates a Buy, 3.0 a Hold, 4.0 a Sell and 5.0 a Stong Sell. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and set a $17.00 price target on shares of Imprivata in a report on Wednesday, May 4th. The company presently has an average rating of “Hold” and an average target price of $16.75. Despite the loss, Imprivata CEO Omar Hussain reported at the time of the earnings announcement, in May, that the company’s core business was strong, with cybersecurity remaining a major concern for the healthcare industry.
Advertisement
Imprivata’s IT technology enables healthcare organizations to securely access, communicate, and transact patient information.
